Clinical Oncology Next-Generation Sequencing Market size is expected to reach nearly USD 2.93 Bn by 2029

Clinical Oncology Next-Generation Sequencing Market
Spread the love

Clinical Oncology Next-Generation Sequencing Market size was valued at US $ 7.86 Bn.in 2022 and the total revenue is expected to grow at 20.7% through 2022 to 2029, reaching nearly US$ 2.93 Bn.

Clinical Oncology Next-Generation Sequencing Market Overview:

The Clinical Oncology Next-Generation Sequencing Market research provides a full competition picture, including market share and company profiles of the major players in the worldwide industry. The scope of the research covers a complete examination of the Clinical Oncology Next-Generation Sequencing Market, as well as the causes for variances in the industry’s growth in different areas.

Market Scope:

To locate and collect material appropriate for this study, this research study makes considerable use of secondary sources, directories, and databases such as annual reports, press releases, journals, corporate websites, and databases.

Dynamics:

The clinical oncology next-generation sequencing market is anticipated to take the lead in the upcoming years due to the rising incidence of cancer and technological advancements in the sector. Furthermore, it is anticipated that over the forecast period, single-gene research would lose ground to NGS, creating significant market potential prospects.

The American Cancer Society estimates that there were 1.7 million more instances of cancer and 0.6 million cancer deaths in the country in 2019. The four most common cancer types worldwide are lung, prostate, bladder, and female breast cancer, which together account for 43% of all new cancer cases. As a result, the need for clinical oncology next-generation sequencing is anticipated to expand as cancer incidence rates rise globally.

Sample Request For Clinical Oncology Next-Generation Sequencing Market  :  https://www.maximizemarketresearch.com/request-sample/100383 

Segmentation:

by Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing Centrifuges

by Workflow

• Pre Sequencing
• Sequencing
• Data Analysis

by Application

• Screening
• Companion Diagnostics
• Other Diagnostics

by End-User

• Hospitals
• Clinics
• Laboratories

Sample Request For Clinical Oncology Next-Generation Sequencing Market  :  https://www.maximizemarketresearch.com/request-sample/100383 

Key Players:  The entire approach involves a review of the financial reports of the major market participants. Following the determination of the overall market size, the complete market was divided into many segments and sub-segments and checked with key industry professionals such as CEOs, VPs, directors, and marketing executives. The major players in the Clinical Oncology Next-Generation Sequencing Market are

• Illumina, Inc.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• F. Hoffman-La Roche Technologies
• Agilent Technologies
• Myriad Genetics
• Foundation Medicine
• Pacific Bioscience
• Oxford Nanopore Technologies Ltd.
• Beijing Genomics Institute (BGI)
• Perkin Elmer, Inc.
• Paradigm Diagnostics
• Caris Life Sciences
• Partek, Inc.
• Eurofins Scientific S.E.
• Bio Rad Laboratories, Inc.
• Other Key Players

Regional Analysis: The region portion of the Clinical Oncology Next-Generation Sequencing Market study also includes individual market affecting elements and changes in legislation in the market that affect present and future market trends. Current and future trends are discussed in order to estimate the entire market potential and to highlight profitable trends in order to obtain a firmer footing. Geographic market assessment is based on the existing scenario and predicted developments.

Sample Request For Clinical Oncology Next-Generation Sequencing Market  :  https://www.maximizemarketresearch.com/request-sample/100383 

 COVID-19 Impact Analysis on Clinical Oncology Next-Generation Sequencing Market:

Following the outbreak of the pandemic, end-user sectors where Clinical Oncology Next-Generation Sequencing Market are used had a fall in growth from January to May in a variety of countries, including China, Italy, Germany, the United Kingdom, the United States, Spain, France, and India, due to a suspension in operations. This resulted in a major decrease in the revenues of firms operating in these industries and, as a consequence, in demand for Clinical Oncology Next-Generation Sequencing Market manufacturers, influencing the growth of the Clinical Oncology Next-Generation Sequencing Market in 2020. With lockdowns and a rising number of COVID-19 cases throughout the world, the demand for Clinical Oncology Next-Generation Sequencing Market from end-user businesses has decreased significantly.

Key Questions answered in the Clinical Oncology Next-Generation Sequencing Market Report are:

  • Which are the major companies in the Clinical Oncology Next-Generation Sequencing Market?
  • Which is the potential market for Clinical Oncology Next-Generation Sequencing Market in terms of the region?
  • What are the opportunities for new market entrants?
  • What is expected to drive the growth of the market in the next seven years?

About Us:

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

Contact Us:

MAXIMIZE MARKET RESEARCH PVT. LTD.
⮝ 444 West Lake Street, Floor 17,
Chicago, IL, 60606, USA.
✆ +1 800 507 4489
✆ +91 9607365656
[email protected]
www.maximizemarketresearch.com


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →